Clinical Scorecard: A Modern Overview of Primary Membranous Nephropathy
At a Glance
Category
Detail
Condition
Primary Membranous Nephropathy
Key Mechanisms
Autoantibodies targeting podocyte-associated antigens, primarily phospholipase A2-receptor (PLA2R), leading to immune complex formation and proteinuria.
Target Population
Middle-aged adults, primarily aged 30-50 years.
Care Setting
Nephrology clinics and outpatient settings.
Key Highlights
PMN is characterized by nephrotic syndrome and can lead to end-stage kidney disease (ESKD).
Treatment includes supportive anti-proteinuric therapy and immunosuppression based on KDIGO risk stratification.
PLA2R antibody levels can be monitored to assess treatment response.
Spontaneous remission occurs in about one-third of cases.
Transplantation is the optimal therapy for ESKD, but recurrence is common.
Guideline-Based Recommendations
Diagnosis
Diagnosis is confirmed by detecting PLA2R antibodies and assessing kidney biopsy for PLA2R positivity.
Management
Low-risk cases may be monitored; moderate to high-risk cases should receive rituximab; very high-risk cases may require alternating steroids and cyclophosphamide.
Monitoring & Follow-up
Follow PLA2R titers to assess response in positive cases; monitor for reemergence of antibodies indicating potential relapse.
Risks
Risks include progression to ESKD and complications from nephrotic syndrome such as thromboembolism.
Patient & Prescribing Data
Patients diagnosed with primary membranous nephropathy, particularly those with nephrotic syndrome.
Rituximab shows a response rate of 60-80% in moderate to high-risk cases.
Clinical Best Practices
Utilize KDIGO-based risk stratification for treatment decisions.
Consider alternative therapies like obinutuzumab or ofatumumab in cases of rituximab resistance.
Regularly assess kidney function and proteinuria in all patients.
Ahead of ISC2026 in Prague, Jennifer Van Eyk explains how scalable LC-MS workflows and single-cell proteomics are helping reveal the biological differences that could make precision medicine a clinical reality
